Tag: alteplase
IRIS data shed new light on how treatment delays may impact...
A collaboration analysing several major clinical trials has found that endovascular therapy (EVT) plus intravenous thrombolysis (IVT) is likely to be superior to EVT...
Tenecteplase linked to higher haemorrhage rates than alteplase in no-thrombectomy stroke...
Intravenous tenecteplase was associated with a higher rate of intracranial haemorrhage (ICH), as compared to alteplase, in a recent analysis of real-world data from...
Dual antiplatelet therapy comparable to thrombolysis in minor, non-disabling ischaemic stroke
Among Chinese patients with minor, non-disabling stroke presenting <4.5 hours from symptom onset, dual antiplatelet therapy (DAPT) has been found to be non-inferior to...
Chinese TRACE II trial deems tenecteplase non-inferior to alteplase in ischaemic...
New data on intravenous tenecteplase indicate that it can achieve comparable efficacy and safety to alteplase in treating stroke—and, as such, may be used...
European Stroke Organisation taskforce delivers update on thrombolytic drug shortages
The thrombolysis taskforce of the European Stroke Organisation (ESO) executive committee has provided an update on current shortages of alteplase and tenecteplase, detailing outcomes...
World Stroke Congress bolsters evidence on optimal thrombectomy and thrombolysis approaches
While much-needed improvements to existing triage and transport protocols for acute stroke patients were a leading topic of focus on World Stroke Day (29...
Tenecteplase offers “incredible opportunity” to optimise thrombolytic stroke treatments
Earlier this year, results from the Canadian AcT (Alteplase compared to tenecteplase) randomised controlled trial (RCT) were delivered for the first time at the...
US study bolsters recent evidence supporting tenecteplase in ischaemic stroke care
Tenecteplase, a newer-generation intravenous thrombolysis (IVT) drug, has outperformed the traditional treatment (alteplase) for ischaemic strokes in several key areas, demonstrating better health outcomes...
Tenecteplase shown to be effective for acute ischaemic stroke in large...
In what is claimed to be the largest stroke clinical trial ever run in Canada, researchers have shown that tenecteplase—a safe, well-tolerated drug commonly...
Study findings encourage direct EVT approaches over bridging thrombolysis in select...
A retrospective study involving more than 200 patients has indicated that ‘bridging thrombolysis’ may not be associated with improved functional outcomes in stroke patients...
Preliminary data indicate improved neurological outcomes with alteplase versus placebo
As per early findings from the CHOICE randomised controlled trial (RCT), the use of adjunct, intra-arterial alteplase—among patients with large vessel occlusion (LVO) acute...
Newer clot-busting medication may someday increase time window for stroke treatment
In a phase 2a clinical trial in China, the clot-busting medication tenecteplase has been shown to be effective in restoring blood flow to the...
LINNC 2021: ESCAPE-NEXT trial may bring “dream” of combining neuroprotection with...
At this year’s LINNC Paris Course (14–16 September, Paris, France and virtual), audiences heard that the ESCAPE-NEXT trial (sponsored by NoNO Inc.), which has already started enrolling...
EXTEND-IA TNK Part 2 trial finds no benefit of higher tenecteplase...
With the original trial demonstrating a higher incidence of substantial reperfusion with tenecteplase compared with alteplase prior to endovascular therapy, EXTEND-IA TNK Part 2...
Alteplase at 0.6mg/kg for stroke with unknown time of onset is...
Although an acceptable safety profile was demonstrated for MRI-guided thrombolysis with alteplase at 0.6mg/kg for stroke with unknown time of onset, the latter approach...
Tenecteplase reduces the need for thrombectomy compared to alteplase
Results from the Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke (EXTEND-IA TNK) study show that the use of tenecteplase (0.25mg/kg) led to...
